압타바이오

293780KOSDAQ자연과학 및 공학 연구개발업

52.7 / 100

Reference Date: 2026-04-13

Financial Score18.0 / 40

News Sentiment17.7 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Slightly down 1.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

AptaBio is a specialized pharmaceutical company developing innovative drugs based on three platform technologies: oxidative stress modulation, CAF Modulation, and aptamer-drug conjugate (Apta-DC). The company focuses on drug pipeline development, including eight therapeutic candidates, and expanded into health functional food ODM and pet care businesses through its newly established New Business Division in 2023. Key revenue streams include technology fees, reagent sales, and product sales from new business segments.

Number of Employees

45people

Average Salary

57.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

4.17Industry Average 3.822.5Point

Higher than industry avg (caution)

ROE

-32.25Industry Average -32.113.5Point

In line with industry avg

Debt Ratio

6.63Industry Average 7.524.0Point

In line with industry avg

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲473.9% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -34.8% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 5Neutral 0Negative 0Average Sentiment Score 75

Positive
압타바이오 “美 학회서 ‘암연관섬유아세포 표적약’ 기술이전 추진...
압타바이오가 미국 학회에서 암연관섬유아세포 표적 항암제 후보물질 'APX-343A'의 기술이전을 추진하고 머크와 병용임상도 계획 중이다.
Positive
압타바이오, 美AACR서 면역항암제·혈액암치료제 내성 극복 연구 결과...
압타바이오가 미국암연구학회(AACR)에 참가해 차세대 면역항암제 APX-343A와 혈액암 치료제 Apta-16의 연구 성과를 포스터 발표로 공개한다.
Positive
압타바이오, AACR 2026서 차세대 면역항암제 연구 성과 발표
압타바이오가 AACR 2026에서 차세대 면역항암제 'APX-343A'와 혈액암 치료제 'Apta-16'의 연구 성과를 발표할 예정이다.

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 7,000Won52-week high 10,44052-week low 6,110

1-month return3.0Point

1m -1.55% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral기업설명회(IR)개최2026-04-06
Neutral본점소재지변경2026-04-01
Neutral정기주주총회결과2026-03-31
Neutral기업설명회(IR)개최2026-03-27
Neutral기업설명회(IR)개최2026-03-26